Ctt Pharmaceutical Holdings Stock Net Income
| CTTH Stock | USD 0.08 0 4.62% |
As of the 28th of January, CTT Pharmaceutical shows the mean deviation of 8.33, and Risk Adjusted Performance of 0.0702. CTT Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
CTT Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CTT Pharmaceutical's valuation are provided below:CTT Pharmaceutical Holdings does not now have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. CTT |
CTT Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CTT Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CTT Pharmaceutical.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in CTT Pharmaceutical on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding CTT Pharmaceutical Holdings or generate 0.0% return on investment in CTT Pharmaceutical over 90 days. CTT Pharmaceutical is related to or competes with Procyon. CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treat... More
CTT Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CTT Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CTT Pharmaceutical Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.06 | |||
| Information Ratio | 0.0764 | |||
| Maximum Drawdown | 70.25 | |||
| Value At Risk | (15.58) | |||
| Potential Upside | 21.39 |
CTT Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CTT Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CTT Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use CTT Pharmaceutical historical prices to predict the future CTT Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0702 | |||
| Jensen Alpha | 0.8208 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.0886 | |||
| Treynor Ratio | 0.3186 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CTT Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CTT Pharmaceutical January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0702 | |||
| Market Risk Adjusted Performance | 0.3286 | |||
| Mean Deviation | 8.33 | |||
| Semi Deviation | 8.64 | |||
| Downside Deviation | 11.06 | |||
| Coefficient Of Variation | 1211.03 | |||
| Standard Deviation | 12.82 | |||
| Variance | 164.32 | |||
| Information Ratio | 0.0764 | |||
| Jensen Alpha | 0.8208 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.0886 | |||
| Treynor Ratio | 0.3186 | |||
| Maximum Drawdown | 70.25 | |||
| Value At Risk | (15.58) | |||
| Potential Upside | 21.39 | |||
| Downside Variance | 122.29 | |||
| Semi Variance | 74.64 | |||
| Expected Short fall | (10.74) | |||
| Skewness | 1.4 | |||
| Kurtosis | 4.24 |
CTT Pharmaceutical Backtested Returns
CTT Pharmaceutical appears to be out of control, given 3 months investment horizon. CTT Pharmaceutical secures Sharpe Ratio (or Efficiency) of 0.0696, which signifies that the company had a 0.0696 % return per unit of volatility over the last 3 months. By analyzing CTT Pharmaceutical's technical indicators, you can evaluate if the expected return of 0.91% is justified by implied risk. Please makes use of CTT Pharmaceutical's mean deviation of 8.33, and Risk Adjusted Performance of 0.0702 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, CTT Pharmaceutical holds a performance score of 5. The firm shows a Beta (market volatility) of 3.29, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CTT Pharmaceutical will likely underperform. Please check CTT Pharmaceutical's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether CTT Pharmaceutical's price patterns will revert.
Auto-correlation | 0.07 |
Virtually no predictability
CTT Pharmaceutical Holdings has virtually no predictability. Overlapping area represents the amount of predictability between CTT Pharmaceutical time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CTT Pharmaceutical price movement. The serial correlation of 0.07 indicates that barely 7.0% of current CTT Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.07 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CTT Pharmaceutical Holdings reported net income of (1.38 Million). This is 100.4% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.24% higher than that of the company.
CTT Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTT Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CTT Pharmaceutical could also be used in its relative valuation, which is a method of valuing CTT Pharmaceutical by comparing valuation metrics of similar companies.CTT Pharmaceutical is currently under evaluation in net income category among its peers.
CTT Fundamentals
| Return On Equity | -4.49 | |||
| Return On Asset | -1.54 | |||
| Current Valuation | 18.87 M | |||
| Shares Outstanding | 21.32 M | |||
| Price To Earning | (3.00) X | |||
| Price To Book | 10.64 X | |||
| Revenue | 40 K | |||
| Net Income | (1.38 M) | |||
| Cash And Equivalents | 32.12 K | |||
| Total Debt | 87.62 K | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 5.01 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (145.16 K) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.14 | |||
| Market Capitalization | 16.17 M | |||
| Total Asset | 186.54 K | |||
| Net Asset | 186.54 K |
About CTT Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CTT Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTT Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTT Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CTT Pink Sheet
CTT Pharmaceutical financial ratios help investors to determine whether CTT Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CTT with respect to the benefits of owning CTT Pharmaceutical security.